KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to $11.4 million.

  • Supernus Pharmaceuticals' Other Non-Current Liabilities fell 7563.43% to $11.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.4 million, marking a year-over-year decrease of 7563.43%. This contributed to the annual value of $47.3 million for FY2024, which is 1143.12% down from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Other Non-Current Liabilities of $11.4 million as of Q3 2025, which was down 7563.43% from $7.8 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' 5-year Other Non-Current Liabilities high stood at $80.5 million for Q4 2021, and its period low was $7.8 million during Q2 2025.
  • Moreover, its 5-year median value for Other Non-Current Liabilities was $53.4 million (2023), whereas its average is $49.9 million.
  • As far as peak fluctuations go, Supernus Pharmaceuticals' Other Non-Current Liabilities soared by 37418.66% in 2021, and later plummeted by 8382.92% in 2025.
  • Supernus Pharmaceuticals' Other Non-Current Liabilities (Quarter) stood at $80.5 million in 2021, then plummeted by 31.7% to $55.0 million in 2022, then fell by 2.76% to $53.4 million in 2023, then decreased by 11.43% to $47.3 million in 2024, then crashed by 75.82% to $11.4 million in 2025.
  • Its Other Non-Current Liabilities was $11.4 million in Q3 2025, compared to $7.8 million in Q2 2025 and $30.0 million in Q1 2025.